Literature DB >> 25452296

Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome.

Catherine Jones1, Yair Levy1, Alex W Tong2.   

Abstract

Polycythaemia vera (PV) is a clonal disorder of bone marrow stem cells characterised by erythrocytosis. Diagnosis of PV requires exclusion of secondary causes of polycythaemia. It has been held that an elevated erythropoietin (Epo) level strongly indicates secondary erythrocytosis and excludes PV diagnosis, to the extent that the reduced serum Epo level is currently listed as a minor criterion in the WHO classification scheme for PV. However, patients with PV who co-present with Budd-Chiari syndrome have been documented with elevated serum Epo levels. For these patients, identification of the Janus kinase 2 (JAK2) V617F point mutation along with the transient nature of the Epo elevation provides certainty of PV diagnosis, as illustrated by the proband. In this case report, the patient's positive response to cytoreductive therapy (hydroxyurea 500 mg daily) and phlebotomy (750 mL over three phlebotomies) further supports validity of PV diagnosis with elevated Epo. The patient remains on rivaroxaban (Xarelto) for treatment of her portal vein thrombosis. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25452296      PMCID: PMC4256595          DOI: 10.1136/bcr-2014-205663

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  33 in total

1.  Cellular and molecular mechanisms regulating the hepatic erythropoietin expression during acute-phase response: a role for IL-6.

Authors:  Pierluigi Ramadori; Ghayyor Ahmad; Giuliano Ramadori
Journal:  Lab Invest       Date:  2010-05-10       Impact factor: 5.662

2.  The JAK2 V617F mutation is absent in patients with erythrocytosis due to high oxygen affinity hemoglobin variants.

Authors:  Rebecca F McClure; James D Hoyer; Ming Mai
Journal:  Hemoglobin       Date:  2006       Impact factor: 0.849

3.  Successful treatment of acute portal vein thrombosis with rivaroxaban.

Authors:  Sven Pannach; Jana Babatz; Jan Beyer-Westendorf
Journal:  Thromb Haemost       Date:  2013-07-11       Impact factor: 5.249

Review 4.  Budd-Chiari syndrome--a review of the diagnosis and management.

Authors:  M A Fox; J A Fox; Mervyn H Davies
Journal:  Acute Med       Date:  2011

5.  Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis.

Authors:  Paul J Thurmes; David P Steensma
Journal:  Eur J Haematol       Date:  2006-07       Impact factor: 2.997

Review 6.  Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.

Authors:  Ayalew Tefferi
Journal:  Am J Hematol       Date:  2012-03       Impact factor: 10.047

7.  Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival - an 18-year experience.

Authors:  Rupesh Rajani; Tor Melin; Einar Björnsson; Ulrika Broomé; Per Sangfelt; Ake Danielsson; Anders Gustavsson; Olof Grip; Hans Svensson; Lars Lööf; Sven Wallerstedt; Sven H C Almer
Journal:  Liver Int       Date:  2008-08-07       Impact factor: 5.828

8.  Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis.

Authors:  E Rumi; F Passamonti; L Pagano; M Ammirabile; L Arcaini; C Elena; A Flagiello; R Tedesco; C Vercellati; A P Marcello; D Pietra; R Moratti; M Cazzola; M Lazzarino
Journal:  J Intern Med       Date:  2008-09-10       Impact factor: 8.989

9.  Polycythemia and the Budd-Chiari syndrome: study of serum erythropoietin and bone marrow erythroid progenitors.

Authors:  V G Levy; A Ruskone; C Baillou; D Theirman-Duffaud; A Najman; G A Boffa
Journal:  Hepatology       Date:  1985 Sep-Oct       Impact factor: 17.425

10.  Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.

Authors:  Francesco Passamonti; Margherita Maffioli; Domenica Caramazza; Mario Cazzola
Journal:  Oncotarget       Date:  2011-06
View more
  4 in total

1.  Direct oral anticoagulants in rare venous thrombosis.

Authors:  Guido Finazzi; Walter Ageno
Journal:  Intern Emerg Med       Date:  2016-02-13       Impact factor: 3.397

2.  Erythrocytosis caused by giant chromophobe renal cell carcinoma: a case report indicating a 9-year misdiagnosis of polycythemia vera.

Authors:  Renbo Guo; Yiran Liang; Lei Yan; Zhonghua Xu; Juchao Ren
Journal:  Chin J Cancer       Date:  2017-09-06

3.  Genome editing to model and reverse a prevalent mutation associated with myeloproliferative neoplasms.

Authors:  Ron Baik; Stacia K Wyman; Shaheen Kabir; Jacob E Corn
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

4.  JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature.

Authors:  Sevastianos Chatzidavid; Nefeli Giannakopoulou; Panagiotis Theodorou Diamantopoulos; Eleni Gavriilaki; Panagiota Katsiampoura; Eleftheria Lakiotaki; Stratigoula Sakellariou; Nora-Athina Viniou; Georgios Dryllis
Journal:  Thromb J       Date:  2021-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.